Sarepta Therapeutics (NASDAQ:SRPT) Announces Earnings Results, Misses Estimates By $2.71 EPS

Sarepta Therapeutics (NASDAQ:SRPT) issued its quarterly earnings results on Wednesday. The biotechnology company reported ($3.58) EPS for the quarter, missing analysts’ consensus estimates of ($0.87) by ($2.71), FiscalAI reports. Sarepta Therapeutics had a negative net margin of 11.25% and a negative return on equity of 4.85%. During the same period in the previous year, the company posted $1.90 earnings per share. Sarepta Therapeutics’s quarterly revenue was down 32.7% on a year-over-year basis.

Here are the key takeaways from Sarepta Therapeutics’ conference call:

• Ended 2025 with $954 million in cash and investments and expects to be cash‑flow positive and non‑GAAP profitable in 2026 while maintaining pipeline and commercial investments (2026 non‑GAAP OpEx guide $800–$900M).
• ELEVIDYS uncertainty has largely been addressed (updated label/traditional approval for ambulatory 4+), and a sirolimus pretreatment study for non‑ambulatory patients is enrolling, but persistent patient/physician hesitancy and long enrollment‑to‑infusion timelines are expected to dampen near‑term ELEVIDYS revenue and drove conservative 2026 guidance.
• The PMO franchise remained durable (Q4 PMO revenue $259M) with >90% compliance and strong real‑world evidence; Sarepta has a late‑Q1 FDA meeting and briefing book to pursue transitioning AMONDYS and VYONDYS to traditional approvals based on ESSENCE and long‑term safety data.
• Sarepta’s siRNA pipeline advanced to five clinical‑stage programs (DM1, FSHD, IPF, SCA2, Huntington); preliminary DM1/FSHD PK/PD/proof‑of‑concept data are expected by quarter‑end with multiple value‑creating milestones over the next 12–18 months.
• CEO Doug Ingram said he intends to retire around the end of 2026 and the board has launched an internal and external search, creating near‑term succession and execution risk.

Sarepta Therapeutics Stock Performance

Shares of NASDAQ:SRPT traded up $0.13 during trading on Wednesday, hitting $18.97. 2,218,922 shares of the company traded hands, compared to its average volume of 2,082,896. The company has a quick ratio of 1.79, a current ratio of 2.95 and a debt-to-equity ratio of 0.78. The business’s fifty day moving average is $20.61 and its 200-day moving average is $20.25. The stock has a market capitalization of $1.99 billion, a price-to-earnings ratio of -6.30, a PEG ratio of 0.47 and a beta of 0.39. Sarepta Therapeutics has a one year low of $10.41 and a one year high of $109.55.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on SRPT. Royal Bank Of Canada lifted their price target on shares of Sarepta Therapeutics from $16.00 to $18.00 and gave the stock a “sector perform” rating in a research note on Thursday, January 8th. Robert W. Baird dropped their target price on shares of Sarepta Therapeutics from $21.00 to $15.00 and set a “neutral” rating for the company in a research report on Tuesday, November 4th. Piper Sandler increased their price target on shares of Sarepta Therapeutics from $15.00 to $16.00 and gave the stock a “neutral” rating in a research report on Thursday, October 30th. Guggenheim decreased their price target on Sarepta Therapeutics from $22.00 to $19.00 and set a “buy” rating for the company in a research note on Wednesday, November 5th. Finally, Wedbush upped their price objective on Sarepta Therapeutics from $32.00 to $34.00 and gave the company an “outperform” rating in a research note on Friday, January 23rd. Nine equities research analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and six have assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $33.84.

Insider Buying and Selling

In other Sarepta Therapeutics news, COO Ian Michael Estepan sold 13,187 shares of the stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $22.31, for a total value of $294,201.97. Following the sale, the chief operating officer directly owned 193,300 shares of the company’s stock, valued at $4,312,523. This trade represents a 6.39% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 7.60% of the stock is currently owned by insiders.

Institutional Trading of Sarepta Therapeutics

A number of large investors have recently modified their holdings of SRPT. AQR Capital Management LLC increased its stake in shares of Sarepta Therapeutics by 454.6% in the fourth quarter. AQR Capital Management LLC now owns 7,796,535 shares of the biotechnology company’s stock valued at $167,781,000 after purchasing an additional 6,390,860 shares during the period. Amundi increased its position in Sarepta Therapeutics by 378.2% in the 3rd quarter. Amundi now owns 969,826 shares of the biotechnology company’s stock valued at $18,689,000 after acquiring an additional 767,026 shares during the period. Millennium Management LLC raised its stake in Sarepta Therapeutics by 251.9% during the 4th quarter. Millennium Management LLC now owns 1,000,109 shares of the biotechnology company’s stock valued at $21,522,000 after acquiring an additional 715,899 shares in the last quarter. Invesco Ltd. boosted its position in Sarepta Therapeutics by 242.0% during the 3rd quarter. Invesco Ltd. now owns 832,638 shares of the biotechnology company’s stock worth $16,045,000 after acquiring an additional 589,157 shares during the period. Finally, Opaleye Management Inc. bought a new position in shares of Sarepta Therapeutics in the second quarter worth $8,550,000. Institutional investors and hedge funds own 86.68% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.